Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
07 nov. 2022 09h00 HE
|
Novan, Inc.
DURHAM, N.C., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its third quarter 2022 financial results on Monday,...
EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
21 oct. 2022 08h35 HE
|
Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced...
EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®
21 oct. 2022 08h35 HE
|
Novan, Inc.
DURHAM, N.C. and COPENHAGEN, Denmark, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), EPI Health, a Novan Company, and MC2 Therapeutics today announced that...
Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference®
14 oct. 2022 08h30 HE
|
Novan, Inc.
DURHAM, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN) and EPI Health, a Novan Company, today announced that eight abstracts have been accepted for...
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
15 sept. 2022 08h00 HE
|
Novan, Inc.
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis ...
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
11 août 2022 06h30 HE
|
Novan, Inc.
– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the...
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
04 août 2022 09h05 HE
|
Novan, Inc.
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday,...
Novan Satisfies $16.5 Million Outstanding Promissory Note
19 juil. 2022 08h30 HE
|
Novan, Inc.
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations – – Novan saves $11.1 million in principal and...
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
13 juin 2022 16h05 HE
|
Novan, Inc.
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering...
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
09 juin 2022 08h30 HE
|
Novan, Inc.
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to...